to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia
NCT ID: NCT02056847
Last Updated: 2018-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
313 participants
INTERVENTIONAL
2013-09-30
2017-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
: To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG).
H0: µT-µC ≥ 0.4 vs H1: µT-µC \< 0.4
µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Pioglitazone and Rosiglitazone on Atherosclerotic and Inflammatory Markers in Patients With Metabolic Syndrome
NCT00314561
Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management
NCT02315287
A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
NCT03499704
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
NCT01183013
Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease
NCT03796975
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Site: Multi-centers in Korea
Period: For 24months after IRB approval at each site (Including 12months of subject enrollment period)
Efficacy End points
A. Primary end point The change of HbA1c before and after taking LIVALO
B. Secondary end point
1. Incidence of diabetes within 1year after registration (based; FPG ≥126mg/dL or to need taking diabetes medication)
2. Incidence of major cardiovascular (TLR-MACE) events within 1 year after registration
3. Incidence of total cardiovascular (TVR-MACE) events within 1 year after registration
4. The change of the lipid composition (T-chol, TG, LDL-C, HDL-C, ApoA1/ApoB)
5. The changes of hs-CRP
6. The changes of Adiponectin
7. The change of blood glucose and Insulin levels FPG(Fasting Plasma Glucose) Fasting Serum Insulin HOMA IR \[fasting insulin(µIU/mL) X fasting glucose(mg/dL)\]/405 HOMA β \[360 X fasting insulin(µIU/mL)\]/\[fasting glucose(mg/dL)-63\]
Statistical Methods
1. Efficacy A. Primary efficacy endpoint analysis Describe statistics of basic about the HbA1c variation before and after taking LIVALO by groups. In order to verify noninferiority of test drug, check that upper limit of confidence interval of the one-sided 97.5% is less than 0.4% about difference of HbA1c variation between the control group and the test group, before and after taking LIVALO.
B. Secondary efficacy endpoint analysis Continuous variables
:Present the mean, standard deviation, minimum, and maximum values for TC, TG, LDL-C, HDL-C, Fasting serum insulin, Fasting plasma glucose and HOMA IR, HOMA β etc. by each visit and in each group. In comparison with intergroup, using two-sample t-test for normal distribution and using Wilcoxon rank sum test for non-normal distribution. Also In comparison with the same group, using paired t-test for normal distribution and using Wilcoxon signed rank test for non-normal distribution.
Discrete variables
: The number and percentage of the subjects for incidence of DM and cardiovascular event are described of each group and the ratio of the intergroup comparison use χ2-test or Fisher's exact test.
2. Safety All the AEs and the ADRs which manifested more than once are described by the frequency and percentage of each group and use χ2-test or Fisher's exact test for intergroup comparison about the rate of AEs and ADRs Laboratory tests and vital signs are analyzed descriptive statistics quantity of each group, and in comparison with intergroup, use two-sample t-test for normal distribution and use Wilcoxon rank sum test for non-normal distribution. Also, In comparison with the same group, use paired t-test for normal distribution and use Wilcoxon signed rank test for non-normal distribution.
Clinical laboratory test is analyzed the frequency and percentage of the outside normal range of subjects, and using χ2-test or Fisher's exact test with intergroup.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pitavastatin calcium 4mg
Pitavastatin calcium (LIVALO®) 4mg, once a day
Pitavastatin calcium 4mg
taking once a day
Pitavastatin calcium 2mg
Pitavastatin calcium (LIVALO®) 2mg, once a day
Pitavastatin calcium 2mg
Taking once a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pitavastatin calcium 4mg
taking once a day
Pitavastatin calcium 2mg
Taking once a day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient who voluntarily sign on written informed consent form
3. Patient who LDL-C ≥ 100mg/dl or was diagnosed with hyperlipidemia
4. Patient who was suspected with Imparied Fasting Glucose (IFG) and satisfy FPG level ≥ 100mg/dL and \< 126mg/dL when FPG measured twice.
Exclusion Criteria
2. Patient who has been diagnosed with Type1, Type2 DM or secondary DM(diabetes mellitus) at the screening visit (Diagnostic criteria of DM: HbA1c≥ 6.5%)
3. Patient who has received antidiabetic within 6weeks to the screening visit
4. Patient who has been taking insulin continuously or to be needed in the future
5. Patient who has a history of gastrectomy
6. Patient who is suspected or diagnosed with malignant tumor within last 10 years
7. Patient who has serious pancreatic disease or endocrine disorders
8. Patient who currently takes Cyclosporine
9. Patient who has a medical history of hypersensitivity to Pitavastatin calcium
10. Patient who has suspected renal failure (serum creatinine ≥2.0 mg/dL)
11. Patient who has suspected liver dysfunction (more than 2.5 times the upper limit of normal AST or ALT)
12. Patient who has more than 3 times the upper limit of normal CPK
13. Patient who is breastfeeding, pregnant or planning pregnancy
14. Patient who deemed inappropriate as subject in the opinion of the Principal Investigator or Investigator
20 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Catholic University of Korea
OTHER
Kyunghee University Medical Center
OTHER
Korea University Guro Hospital
OTHER
Dong-A University Hospital
OTHER
Seoul National University Bundang Hospital
OTHER
Samsung Medical Center
OTHER
Seoul National University Hospital
OTHER
Ajou University School of Medicine
OTHER
Gangnam Severance Hospital
OTHER
Severance Hospital
OTHER
Yeungnam University Hospital
OTHER
Ulsan University Hospital
OTHER
Eulji University Hospital
OTHER
Asan Medical Center
OTHER
Chonnam National University Hospital
OTHER
Chonbuk National University Hospital
OTHER
Chungnam National University Hospital
OTHER
Hallym University Medical Center
OTHER
JW Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
NamSik Chung, M.D., Ph D.
Role: PRINCIPAL_INVESTIGATOR
Severance Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
JW pharmaceutical
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JW-PTV-713
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.